Adaptive Biotechnologies (HAM:1HM) Beta: N/A (As of Jul. 04, 2026)


HAM:1HM Adaptive Biotechnologies Corp HAM:1HM
47 GF Score
Price €18.54
GF Value €8.80
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-04), Adaptive Biotechnologies's Beta is Not available.

Adaptive Biotechnologies  (HAM:1HM) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Adaptive Biotechnologies Beta Related Terms

Adaptive Biotechnologies Beta Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Beta Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adaptive Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:1HM
47GF Score
Adaptive Biotechnologies Corp HAM:1HM
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Adaptive Biotechnologies (HAM:1HM) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of €18.54 is trading 110.7% above its estimated GF Value™ of €8.80. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for HAM:1HM:

  • Beta: N/A
  • GF Value™: €8.80 vs. price of €18.54 (110.7% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the HAM:1HM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges ADPT:USA1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
47GF Score

Get the complete analysis for HAM:1HM

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.54
Price
€8.80
GF Value